International, randomized, double blind, phase 3 trial of Axitinib (AG-013736) versus placebo given in advanced non small cell lung cancer patients receiving cisplatin and gemcitabine as first line treatment.

Trial Profile

International, randomized, double blind, phase 3 trial of Axitinib (AG-013736) versus placebo given in advanced non small cell lung cancer patients receiving cisplatin and gemcitabine as first line treatment.

Suspended
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2011

At a glance

  • Drugs Axitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top